Avaleht › Leukeemia › Massachusetts › Boston
Leukeemia kliinilised uuringud linnas Boston, MA
25 uuringut haiguse Leukeemia jaoks otsivad osalejaid linnas Boston ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
VärbamineFaas 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Värbamine
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
VärbamineFaas 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
VärbamineFaas 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
VärbamineFaas 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
VärbamineFaas 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
VärbamineFaas 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
VärbamineFaas 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Värbamine
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
VärbamineTerved vabatahtlikud oodatud
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
VärbamineFaas 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
VärbamineFaas 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
VärbamineFaas 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
VärbamineFaas 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
VärbamineVaatlusuuring
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
VärbamineFaas 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Värbamine
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
VärbamineVaatlusuuring
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
VärbamineFaas 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
VärbamineFaas 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
VärbamineFaas 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
VärbamineFaas 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
VärbamineFaas 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Värbamine
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Värbamine
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Leukeemia uuringud teistes linnades
- Houston, TX28 uuringut
- New York City, NY19 uuringut
- Los Angeles, CA16 uuringut
- Chicago, IL16 uuringut
- Durham, NC13 uuringut
- Baldwin Park, CA12 uuringut
- Columbus, OH12 uuringut
- Nashville, TN12 uuringut
- Philadelphia, PA12 uuringut
- Milwaukee, WI11 uuringut
- Atlanta, GA11 uuringut
- Seattle, WA11 uuringut
Muud uuringud linnas Boston
- Rinnavähk111 uuringut
- Mitteväikerakuline kopsuvähk90 uuringut
- Vähk (kõik liigid)86 uuringut
- Käär- ja pärasoolevähk63 uuringut
- Metastaatiline vähk63 uuringut
- Kopsuvähk62 uuringut
- Munasarjavähk61 uuringut
- Eesnäärmevähk59 uuringut
- Depressioon52 uuringut
- Endomeetriumivähk50 uuringut
- Südamepuudulikkus44 uuringut
- Äge müeloidne leukeemia44 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.